Tobramycin Inhalation Powder; Placebo
Проводит Новартис Фарма АГ
Страница компанииA Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00918957/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 6–21 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 62 чел. во всех странах исследования.
- Плановая дата окончания (05.2011) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 23
Критерии включения
- Written informed consent given by adults or by the parents/legal guardian in combination with the patient's assent, if capable of assenting, before any assessment was performed
- Confirmed diagnosis of Cystic Fibrosis (CF) by the presence of one or more clinical features of CF in addition to:
- a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L; or
- identification of well-characterized disease-causing mutations in each CFTR gene; or
- an abnormal nasal transepithelial potential difference characteristic of CF.
- Forced Expiratory Volume in one second (FEV1) at screening must have been ≥25% and ≤80% of normal predicted values for age, sex, and height based on Knudson criteria
- P. aeruginosa must have been present in a sputum/deep-throat cough swab culture (or bronchoalveolar lavage \[BAL\]) within 6 months prior to screening and in the sputum/deep-throat cough swab culture at the screening visit
- Able to expectorate a sputum sample or provide a deep throat cough swab at screening
- Able to comply with all protocol requirements
- Use of an effective means of contraception in females of childbearing potential
- Clinically stable in the opinion of the investigator to be treated according to this protocol
Критерии невключения
- FEV1 at baseline (Visit 2) <25% or >80% of normal predicted values for age, sex, and height based on Knudson criteria, and/or FEV1 at baseline (Visit 2) deviated by ≥10% from the FEV1 measured at screening (Visit 1)
- Any use of inhaled anti-pseudomonal antibiotics within 4 months prior to screening
- Any use of systemic anti-pseudomonal antibiotics within 28 days prior to study drug administration
- Serum creatinine 2 mg/dL or above, blood urea nitrogen (BUN) 40 mg/dL or above, or an abnormal urinalysis defined as 2+ or greater proteinuria
- Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics
- Signs and symptoms of acute pulmonary disease, e.g. pneumonia, pneumothorax
- Administration of any investigational drug within 30 days prior to enrollment
- Any previous exposure to tobramycin dry powder for inhalation (TIP)
- Administration of loop diuretics within 7 days prior to study drug administration
- Initiation of treatment with chronic macrolide therapy within 28 days prior to study drug administration
- Initiation of treatment with dornase alfa within 28 days prior to study drug administration
- Initiation of treatment with inhaled steroids (or increased dose) within 28 days prior to study drug administration
- Initiation of treatment with inhaled hypertonic saline (HS) within 28 days prior to study drug administration
- Personal history of abnormal hearing or family history of abnormal hearing other than typical hearing loss associated with the aging process
- Known abnormal result from any audiology testing (defined as either a unilateral puretone audiometry test showing a threshold elevation >20 dB at any frequency across the frequency range 0.25 kHz to 8 kHz or the absence of emission at the evoked otoacoustic emission test)
- History of sputum culture or throat swab (or BAL) culture yielding Burkholderia cepacia (B. cepacia) within 2 years prior to screening and/or sputum culture yielding B. cepacia at screening
- Hemoptysis of more than 60 mL at any time within 30 days prior to study drug administration
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of evidence of local recurrence or metastases
- Patients with clinically significant laboratory abnormalities (not associated with the study indication) at screening
- Patients or caregivers with a history of noncompliance to medical regimens and patients or caregivers who are considered potentially unreliable
- Pregnant or nursing (lactating) women
- Women of child-bearing potential unless they used two reliable birth control methods
- Other protocol-defined inclusion/exclusion criteria may apply
Источник: ClinicalTrials.gov, NCT00918957 · запись обновлена в реестре 3 октября 2012.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 9
- Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29) — Baseline, Day 29
- Pre-planned Sensitivity Analysis: Absolute Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent (%) Predicted to End of Dosing (Day 29) — Baseline, Day 29
- Post-hoc: Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29) Without Outlier — Baseline, Day 29
Цель исследования
This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00918957 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.